Pfizer or buy Actavis?

Source: bioprospecting 2014-09-04 recently, Bloomberg business week, a foreign media, speculated that Pfizer intended to acquire another company, atvis, after its failure in acquiring AstraZeneca last year, rather than launching a second round of attack on AstraZeneca as the media had speculated earlier Recently, Bloomberg business week, a foreign media, speculated that Pfizer intended to acquire another company, atvis, after its failure to acquire AstraZeneca last year, rather than launch a second round of attack on AstraZeneca as the media had speculated earlier In 2013, after acquiring Warner Chilcott in Ireland, atvis moved its headquarters to Dublin, Ireland Atvis is headquartered in Ireland Pfizer's acquisition of the latter is conducive to its settlement of overseas assets, which is also the main reason for Pfizer's acquisition of atvis In addition, with the expiration of Pfizer's heavyweight patent medicine patents, the acquisition of the world's second largest generic pharmaceutical company is obviously conducive to them to make up for the current decline Atvis, headquartered in Dublin, Ireland and with a subsidiary in PASI PANI, New Jersey, has expanded rapidly around the world through acquisitions Earlier this year, atvis bought forest laboratories for $25 billion If Pfizer's offer is accepted, the difficulty of restructuring is expected to increase But Pfizer's spokesman Joan Campion told Bloomberg Business Weekly that Pfizer CEO Ian read said in the second quarter report, "as long as it can strengthen the company's core business and shareholders' interests, Pfizer will make every effort to strive for acquisition without considering the size of the other party." In the first half of this year, Pfizer increased its acquisition of AstraZeneca several times, but the tenacious AstraZeneca management resisted the pressure and finally let Pfizer's acquisition plan fail AstraZeneca's share price rose rapidly, which seemed to compensate for AstraZeneca's efforts However, for Pfizer, the share price also fell after the failure of the acquisition plan In fact, many analysts are not optimistic about the deal, because another acquisition by Pfizer means another increase in price The final increase in the last acquisition invitation was 117 billion yuan, which is "too expensive" for Pfizer at present It's rainy every night Pfizer's recent life is not easy According to the financial reports of major pharmaceutical companies in the first half of this year, Novartis has replaced Pfizer as No.1 in the pharmaceutical sector, and Pfizer ranks second In fact, the good performance of Roche will also threaten Pfizer's second position.